Product Description
Mesna is used to reduce the risk of hemorrhagic cystitis (a condition that causes inflammation of the bladder and can result in serious bleeding) in people who receive ifosfamide (a medication used for the treatment of cancer). Mesna is in a class of medications called cytoprotectants. (Sourced from: https://medlineplus.gov/druginfo/meds/a613013.html)
Mechanisms of Action: Acrolein Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Biphenotypic Acute Leukemia|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Colorectal Cancer|Liver Transplant|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer|T-Cell Cutaneous Lymphoma|T-Cell Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2025-521227-70-00 |
ProbeTILity | P2 |
Not yet recruiting |
Colorectal Cancer|Prostate Cancer |
2029-03-01 |
12% |
||
NCT05589896 |
PRESERVE I | P2 |
Recruiting |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Biphenotypic Acute Leukemia|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Lymphoma, B-Cell|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|T-Cell Leukemia|T-Cell Cutaneous Lymphoma|Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-05-31 |
12% |
2026-02-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT03577431 |
LITTMUS-MGH | P2 |
Active, not recruiting |
Liver Transplant |
2026-03-31 |
2023-09-22 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/15/2024 |
News Article |
STIX Meme Amplifies Base Memecoins |
|
11/14/2024 |
News Article |
STIX Promotes $DOG on Stickerly to Bring Top Bitcoin Memecoin to the Masses |
|
11/12/2024 |
News Article |
STIX Meme Platform Integrates AI Meme Generator Tool Ahead of Launch |